Usefulness ofl-[methyl-11C] methionine—positron emission tomography as a biological monitoring tool in the treatment of glioma
Authors:
- Tadashi NariaiTNTadashi Nariai
- Yoji TanakaYTYoji Tanaka
- Hiroaki WakimotoHiroaki Wakimoto
- Masaru AoyagiMAMasaru Aoyagi
- Masashi TamakiMTMasashi Tamaki
- Kiichi IshiwataKIKiichi Ishiwata
- Michio SendaMSMichio Senda
- Kenji IshiiKIKenji Ishii
- Kimiyoshi HirakawaKHKimiyoshi Hirakawa
- Kikuo OhnoKOKikuo Ohno
- 1 September 2005
- journal article
- clinical trial
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 103 (3) , 498-507
Abstract
Object The authors retrospectively analyzed the data obtained in patients who had undergone l-[methyl-11C] methionine (MET)—positron emission tomography (PET) studies to clarify the relationship between MET uptake and tumor biological features and to discuss the clinical usefulness of MET-PET studies. Methods One hundred ninety-four patients with cerebral glioma or suspected glioma underwent PET scanning 20 minutes after injection of MET, whose uptake into the tumor was expressed as a ratio to contralateral healthy brain tissue (T/N ratio). Analyses were performed to determine how MET uptake correlated with tumor pathological features and prognosis. The T/N ratios before and after various treatments were also examined. There were significant differences in the T/N ratio among the nonneoplastic lesions, low-grade gliomas, and malignant gliomas. Furthermore, there were significant correlations between patient survival and pretreatment T/N ratios. Among patients with malignant gliomas, a significant difference in survival was observed between cases with and without postoperative tumor remnant based on elevated MET uptake. The MET uptake was heterogeneous even among the homogeneous tumor areas demonstrated on MR imaging. Malignant pathological features were detected in the areas with the highest MET uptake. The effectiveness of radiotherapy or chemotherapy was expressed as a significantly decreased T/N ratio in some of the tumor types. Conclusions The ability of MET-PET to reflect the biological nature of gliomas makes it an excellent method for monitoring active tumor tissue, and treatments based on its findings should provide a powerful clinical protocol in the course of glioma therapy.Keywords
This publication has 31 references indexed in Scilit:
- Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal AbnormalitiesJournal of Clinical Oncology, 2003
- Value of FDG-PET scanning in management of lung cancerThe Lancet, 2002
- Positron emission tomography with injection of methionine as a prognostic factor in gliomaJournal of Neurosurgery, 2001
- Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass LesionsJAMA, 2001
- Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- 11 C-methionine PET for differential diagnosis of low-grade gliomasNeurology, 1998
- The In Vivo Metabolic Pattern of Low-grade Brain Gliomas: A Positron Emission Tomographic Study Using f-18-fluorodeoxyglucose and c-11-L-MethylmethionineNeurosurgery, 1998
- Glioma Invasion in the Central Nervous SystemNeurosurgery, 1996
- A Fully Automatic Multimodality Image Registration AlgorithmJournal of Computer Assisted Tomography, 1995